Document is current
Any future updates will be listed below
-
Authors
Powles, Thomas
Motzer, Robert J.
Escudier, Bernard
Pal, Sumanta
Kollmannsberger, Christian
Pikiel, Joanna
Gurney, Howard
Rha, Sun Young
Park, Se Hoon
Geertsen, Poul F.
Gross-Goupil, Marine
Grande, Enrique
Suarez, Cristina
Markby, David W.
Arroyo, Alan
Dean, Mark
Choueiri, Toni K. https://orcid.org/0000-0002-9201-3217
George, Daniel
- License Information
-
More Information
Article History
Received: 22 November 2017
Revised: 1 May 2018
Accepted: 7 June 2018
First Online: 10 September 2018
Ethics approval and consent to participate
: The study was conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the ethics committee or institutional review board at each center, and all patients provided written informed consent.
: T.P.: advisory/consulting role for AstraZeneca, Bristol-Myers Squibb (BMS), Genentech/Roche, Merck, Exelixis; research funding from AstraZeneca/MedImmune, Roche/Genentech. R.J.M.: advisory/consulting role for Pfizer, Novartis, Eisai, Exelixis; research funding from BMS, Pfizer, Genentech/Roche, Eisai, Exelixis, Novartis. B.E.: advisory/consulting role for Novartis, BMS, Roche, Exelixis, Ipsen, Acceleron Pharma, Bayer; research funding from Novartis and BMS. S.P.: advisory/consulting role for Novartis, Medivation Astellas Pharma, Pfizer, Aveo, Genentech, Exelixis, BMS, GlaxoSmithKline. C.K.: advisory/consulting role for Pfizer, BMS, Novartis, Astellas Pharma. H.G.: advisory/consulting role for Roche, MSD, Ipsen. M.G.G.: advisory/consulting role for Ipsen, Pfizer, BMS, Novartis. E.G.: advisory/consulting role for Ipsen, Pfizer, BMS, Eisai. C.S.: advisory/consulting role for BMS, Pfizer, Bayer, Ipsen; non-financial support from Pfizer and Astellas Pharma. D.W.M., A.A., M.D.: employees and stockholders of Exelixis. T.K.C.: advisory/consulting role for Pfizer, GlaxoSmithKline, Novartis, Merck, Bayer, Eisai, Roche, Prometheus Labs, Foundation Medicine, BMS; research funding from Pfizer, GlaxoSmithKline, Novartis, BMS, Merck, Exelixis, Roche, AstraZeneca, Tracon, Peloton. D.G.: advisory/consulting role for Exelixis, BMS, Astellas Pharma, Dendreon, Innocrin, Pfizer, Sanofi, Bayer; research funding from Exelixis, BMS, Astellas Pharma, Dendreon, Innocrin, Janssen, Novartis, Pfizer, Bayer. All other authors declare no competing interests.
: This study was sponsored by Exelixis, Inc.
